Hjem › Multipelt myelom › Illinois
Multipelt myelom kliniske forsøg i Illinois
31 studier for Multipelt myelom søger deltagere på steder i Illinois.
Byer i Illinois
- Chicago22 studier
- Cicero6 studier
- Evanston4 studier
- Waukegan4 studier
- Springfield4 studier
- Galesburg3 studier
- Peoria3 studier
- North Peoria3 studier
- Bloomington3 studier
- Aurora3 studier
- Decatur3 studier
Officiel studietekst (engelsk)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- og 13 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06948084A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- University of Chicago Medical Center /ID# 278863, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chicago
- Research Site, Park Ridge
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Chicago Medical Center, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Rush University System for Health, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Chicago, Zion
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University Of Illinois Medical Center, Chicago
- Loyola University Medical Center, Maywood
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Northwestern University, Chicago
- University of Chicago, Chicago
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05201781Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT05789303TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06297226Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- University of Illinois at Chicago, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05344833MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Endeavor Health - Swedish Hospital, Chicago
- Endeavor Health - Evanston Hospital, Evanston
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
- og 6 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. aug. 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- og 40 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Loyola University Medical Center, Maywood
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT07280013Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 3. aug. 2026 · NCT06960993Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Loyola University Chicago, Maywood
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07236502A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Hope And Healing Cancer Services /ID# 268536, Hinsdale
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT05650632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699Personalized Autologous Transplant for Multiple Myeloma
- University Illinois Chicago, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. jun. 2026 · NCT04483206Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Anthony's Health, Alton
- Rush - Copley Medical Center, Aurora
- Saint Joseph Medical Center, Bloomington
- og 41 flere
RekruttererFase 3
Alle aldre · Alle køn · Opdateret 10. jun. 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT05243797Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
RekruttererFase 1
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. apr. 2026 · NCT05862012Hypofractionation (Radiation) Trial for Multiple Myeloma
- The University of Chicago Comprehensive Cancer Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT06270888A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 24. mar. 2026 · NCT04988555Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. feb. 2026 · NCT05974150A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- City of Hope at Chicago, Zion
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 20. feb. 2026 · NCT07225738Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
- University of Illinois Cancer Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. dec. 2025 · NCT05192122Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.